"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," BioNTech CEO Ugur Sahin said Tuesday.
Copyright 2020 NPR
"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," BioNTech CEO Ugur Sahin said Tuesday.
Copyright 2020 NPR